3-(4-chlorophenyl)-8-(3-(4-fluorophenoxy)propyl)-8-azabicyclo[3.2.1]octan-3-ol | 1366349-33-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 3-(4-chlorophenyl)-8-(3-(4-fluorophenoxy)propyl)-8-azabicyclo[3.2.1]octan-3-ol
• 英文别名: 3-(4-Chlorophenyl)-8-[3-(4-fluorophenoxy)propyl]-8-azabicyclo[3.2.1]octan-3-ol
• CAS: 1366349-33-8
• 化学式: C₂₂H₂₅ClFNO₂
• 分子量: 389.897
• InChiKey: AWIYLVWAILOVMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)-8-(3-(4-fluorophenoxy)propyl)-8-azabicyclo[3.2.1]octan-3-ol 在 盐酸 作用下， 以722 mg的产率得到3-(4-chlorophenyl)-8-(3-(4-fluorophenoxy)propyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochlroide
  参考文献：
  名称：

  Structure–activity relationship studies of SYA 013, a homopiperazine analog of haloperidol

  摘要：

  Structure-activity relationship studies on 4-(4-(4-chlorophenyl)-1,4-diazepan-1-yl)-1-(4-fluorophenyl) butan-1-one (SYA 013), a homopiperazine analog of haloperidol has resulted in an understanding of the effect of structural modifications on binding affinity at dopamine and serotonin receptor subtypes. Further exploration, using bioisosteric replacement strategies has led to the identification of several new agents including compounds 7, 8, 11 and 12 which satisfy the initial criteria for further exploration as new antipsychotic agents. In addition, compound 18, a D-3 selective tropanol, has been identified as having the potential for further optimization into a useful drug which may combat neuropsychiatric diseases. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2012.01.022
• 作为产物：
  描述：

  3-(4-fluorophenoxy)-1-propanol 在 potassium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 28.0h， 生成 3-(4-chlorophenyl)-8-(3-(4-fluorophenoxy)propyl)-8-azabicyclo[3.2.1]octan-3-ol
  参考文献：
  名称：

  Structure–activity relationship studies of SYA 013, a homopiperazine analog of haloperidol

  摘要：

  Structure-activity relationship studies on 4-(4-(4-chlorophenyl)-1,4-diazepan-1-yl)-1-(4-fluorophenyl) butan-1-one (SYA 013), a homopiperazine analog of haloperidol has resulted in an understanding of the effect of structural modifications on binding affinity at dopamine and serotonin receptor subtypes. Further exploration, using bioisosteric replacement strategies has led to the identification of several new agents including compounds 7, 8, 11 and 12 which satisfy the initial criteria for further exploration as new antipsychotic agents. In addition, compound 18, a D-3 selective tropanol, has been identified as having the potential for further optimization into a useful drug which may combat neuropsychiatric diseases. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2012.01.022